Streptococcus phocae vaccine
The present invention relates to the use of bacteria of the species Streptococcus phocae for the manufacture of a vaccine, to methods for the production of such vaccines, to bacteria of the species Streptococcus phocae for use in a vaccine and to methods for the combating of Streptococcus phocae infection in fish.
1 . A method for combating Streptococcus phocae infection in fish comprising administering a vaccine to fish, wherein the vaccine comprises bacteria of the species Streptoccus phocae.
2 . The method according to claim 1 , wherein the fish are salmonids.
3 . The method according to claim 2 , wherein the fish are Atlantic salmons.
4 . The method according to claim 1 , wherein the bacteria are in an inactivated form.
5 . The method according to claim 1 , wherein said vaccine further comprises
i) additional fish-pathogenic microorganism,
ii) addition fish-pathogenic virus, or
iii) an antigen of (i) or (ii).
6 . The method according to claim 5 , wherein the additional fish-pathogenic microorganism or virus is selected from the group consisting of Vibrio ordalii, Vibrio anguillarum serotype O1, Vibrio anguillarum serotype O2, Aeromonas salmonicida, Flavobacterium columnarae, Flexibacter maritimum, Edwardsiella ictaluri, Edwardsiella tarda, Photobacterium damselae subspecies piscidida, Flavobacterium psychrophilum, Moritella viscosa, Piscirickettsia salmonis, Yersinia ruckeri, Vibrio salmonicida, Infectious Pancreatic Necrotic Disease virus, Infectious Salmon Anaemia virus and Salmon Pancreatic Disease virus.
7 . The method according to claim 1 , wherein the vaccine further comprises an adjuvant.
8 . The method according to claim 1 , wherein said vaccine is in a freeze-dried form.
9 . (canceled)
10 . A method for the production of a vaccine for combating Streptococcus phocae infection, said method comprising the mixing of bacteria of the species Streptococcus phocae in a live attenuated or inactivated form and a pharmaceutically acceptable carrier.
11 . (canceled)
12 . The method of claim 1 , wherein said bacteria are in a live attenuated or inactivated form, and wherein said vaccine comprises a pharmaceutically acceptable carrier.
13 . A vaccine comprising bacteria of the species Streptococcus phocae.
14 . The vaccine according to claim 13 , wherein the bacteria are in an inactivated form.
15 . The vaccine according to claim 13 , wherein the bacteria are in a live attenuated form.
16 . The vaccine according to claim 13 , wherein the vaccine further comprises
i) additional fish-pathogenic microorganism,
ii) addition fish-pathogenic virus, or
iii) an antigen of (i) or (ii).
17 . The vaccine according to claim 16 , wherein the additional fish-pathogenic microorganism or virus is selected from the group consisting of Vibrio ordalii, Vibrio anguillarum serotype O1, Vibrio anguillarum serotype O2, Aeromonas salmonicida, Flavobacterium columnarae, Flexibacter maritimum, Edwardsiella ictaluri, Edwardsiella tarda, Photobacterium damselae subspecies piscidida, Flavobacterium psychrophilum, Moritella viscosa, Piscirickettsia salmonis, Yersinia ruckeri, Vibrio salmonicida, Infectious Pancreatic Necrotic Disease virus, Infectious Salmon Anaemia virus and Salmon Pancreatic Disease virus.
18 . The vaccine according to claim 13 , wherein the vaccine further comprises an adjuvant.
19 . The vaccine according to claim 13 , wherein the vaccine is in a freeze-dried form.
20 . The vaccine according to claim 13 , wherein the vaccine further comprises a pharmaceutically acceptable carrier.
21 . The method according to claim 1 , wherein the bacteria are in a live attenuated form.